With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships

[cafead]

via The recent downturn in the biotechnology sector affected startups in many ways, from the availability of financing to the types of research they pursued. A report J.P. Morgan analysts published late last month suggests yet another ripple effect: a seeming shift in the terms young drugmakers receive in partnership deals.

article source